OrisDX Launches Oro Lesion and Oris Bridge; First and Only Saliva DNA Test for Oral Cavity Cancer with Patient Navigator
First time a DNA-based precision diagnostic is launched into the dental setting where the patient journey begins.
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
First time a DNA-based precision diagnostic is launched into the dental setting where the patient journey begins.
CHICAGO, IL, UNITED STATES, November 16, 2026 /EINPresswire.com/ — OrisDX announces today that Oro Lesion, the company’s noninvasive saliva DNA test, is available as a Laboratory Developed Test regulated under the Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Improvement Amendments (CLIA) certification and the College of American Pathologists (CAP) accreditation process. Oro Lesion is the first noninvasive test for oral cavity squamous cell carcinoma (OCSCC) that analyzes DNA from a saliva-based sample and has been proven to have 94% sensitivity, 98% specificity, a positive predictive value of 96%, and a negative predictive value of 97%. Oro Lesion, available through dental and medical providers, offers people over 18 years old with an indeterminate oral lesion an easy-to-use test they can take in a clinic or in the privacy of their own home.
Head and neck cancer is the sixth most common cancer globally, yet late-stage diagnosis leaves patients with 5-year survival rates as low as 25%. Approximately 1.6 million to 4.9 million adults over the age of 18 are seen by a dentist with an oral lesion that may be cancerous. If detected earlier, the lesion can be removed, with survival as high as 90%.
“As a head and neck cancer survivor, I know how hard it can be to wait for answers when you notice a change in your mouth. Getting it checked promptly by a dental or medical professional and knowing what comes next can make a real difference for patients and their families.”
— Cathy Hapenney, head and neck cancer survivor and advocate
Oro Lesion is designed to detect biomarkers from acquired (somatic) mutations in cancer-related DNA in whole cells collected by agitation of a salivary rinse. A clinician can collect the sample with the Oro Lesion Collection Kit after seeing the lesion during a conventional oral examination, or the kit can be mailed directly to the patient’s home. The salivary sample is sent back to the OrisDX lab for testing through a pre-paid mailer.
At the lab, the salivary sample is analyzed in an automated system to yield a single test result–detected or not-detected for the presence of the biomarkers associated with OCSCC. Results from the Oro Lesion test are turned around in as little as two weeks, and Oris Bridge shares them with the prescribing clinician and patient. If the test is positive, the patient navigation system will support the patient’s journey to a surgeon. There are no restrictions or experience needed to collect the sample.
“Oral cancer is most treatable when it’s caught early, and too many cases aren’t. OrisDX gives clinicians a simple, noninvasive way to find it sooner, with accuracy we have validated in a CLIA-certified, CAP-accredited lab. We designed the test to be accurate, easy for patients to use, and widely accessible,” said Nishant Agrawal, M.D., a UChicago Medicine surgeon and co-inventor of the test.
“Our hope is that earlier detection will save lives.”
— Dr. Nishant Agrawal, M.D., Chair of the Department of Otolaryngology-Head & Neck Surgery at University of Chicago Medicine
“For far too long, patients facing a suspicious oral lesion have found themselves caught in a fragmented gray zone between routine dental care and complex medical oncology—facing anxiety, delays, and invasive unknowns,” said Harald Steltzer, CEO of OrisDX. “With the launch of Oro Lesion, we are directly closing that divide. By arming clinicians with definitive, non-invasive molecular clarity at the earliest point of concern, we aren’t just advancing diagnostics; we are fundamentally reshaping the patient journey. Our mission is to put the individual first, replacing prolonged uncertainty with swift, actionable answers, and ensuring that every patient seamlessly navigates from the dental chair to the right specialized care without falling through the cracks.”
Oro Lesion is available to patients through their healthcare providers in the US. OrisDX has plans to add HPV biomarkers to the test for multicancer detection, which is typically found in the oropharynx. For more information, visit www.orisdx.com/orolesion or call 1-464-888-3940.
Dr. Nishant Agrawal, Chair, Department of Otolaryngology-Head and Neck Surgery, UChicago Medicine, is the inventor of the technology that has been licensed to OrisDX from the University of Chicago Polsky Center. Under the licensing agreement, the University of Chicago and Dr. Agrawal shares in equity and royalties.
About OrisDX
OrisDX is an innovative oral health technology company focused on transforming early cancer detection through advanced molecular diagnostics and interdisciplinary medical collaboration. The company has exclusive intellectual property protecting its noninvasive molecular testing technology for detecting head and neck cancer.
Nathan Steltzer
OrisDX
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery


